[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

YU31795A - Oralne tečne formulacije alendronata - Google Patents

Oralne tečne formulacije alendronata

Info

Publication number
YU31795A
YU31795A YU31795A YU31795A YU31795A YU 31795 A YU31795 A YU 31795A YU 31795 A YU31795 A YU 31795A YU 31795 A YU31795 A YU 31795A YU 31795 A YU31795 A YU 31795A
Authority
YU
Yugoslavia
Prior art keywords
oral liquid
alendronate
alendronate formulations
formulations
liquid alendronate
Prior art date
Application number
YU31795A
Other languages
English (en)
Other versions
YU49354B (sh
Inventor
Gerald Brenner
Ashok Katdare
Denise Pretzer
Donnat Whiteford
Original Assignee
Merc & Co.Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merc & Co.Inc. filed Critical Merc & Co.Inc.
Publication of YU31795A publication Critical patent/YU31795A/sh
Publication of YU49354B publication Critical patent/YU49354B/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Ovaj pronalazak se odnosi na oralne tečne farmaceutske formulacije alendronata, tj., trihidrata mononatrijum 4-amino-1-hidroksibutiliden-1,1-bisfosfinske kiseline za sprečavanje gubitka kostiju kod pacijenata koji imaju teškoće sa gutanjem.Takodje su opisani oblici doza sirupa, vodenog rastvora, rastvora dobijenog iz rekonstituisanog praha alendronata.
YU31795A 1994-05-17 1995-05-17 Oralne tečne formulacije alendronata YU49354B (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/245,289 US5462932A (en) 1994-05-17 1994-05-17 Oral liquid alendronate formulations

Publications (2)

Publication Number Publication Date
YU31795A true YU31795A (sh) 1999-06-15
YU49354B YU49354B (sh) 2005-09-19

Family

ID=22926074

Family Applications (1)

Application Number Title Priority Date Filing Date
YU31795A YU49354B (sh) 1994-05-17 1995-05-17 Oralne tečne formulacije alendronata

Country Status (34)

Country Link
US (1) US5462932A (sh)
EP (1) EP0759757B1 (sh)
JP (1) JP4111536B2 (sh)
KR (1) KR100372966B1 (sh)
CN (1) CN1079672C (sh)
AT (1) ATE222495T1 (sh)
AU (1) AU691634B2 (sh)
CA (1) CA2190148C (sh)
CO (1) CO4600739A1 (sh)
CY (1) CY2336B1 (sh)
CZ (1) CZ285860B6 (sh)
DE (1) DE69527842T2 (sh)
DK (1) DK0759757T3 (sh)
DZ (1) DZ1884A1 (sh)
ES (1) ES2180646T3 (sh)
FI (1) FI118296B (sh)
HK (1) HK1009245A1 (sh)
HR (1) HRP950293B1 (sh)
HU (1) HU220626B1 (sh)
IL (1) IL113651A (sh)
MX (1) MX9605660A (sh)
MY (1) MY112285A (sh)
NO (1) NO310179B1 (sh)
NZ (1) NZ289231A (sh)
PL (1) PL179634B1 (sh)
PT (1) PT759757E (sh)
RU (1) RU2176507C2 (sh)
SI (1) SI0759757T1 (sh)
SK (1) SK281098B6 (sh)
TW (1) TW402501B (sh)
UA (1) UA29505C2 (sh)
WO (1) WO1995031203A1 (sh)
YU (1) YU49354B (sh)
ZA (1) ZA953960B (sh)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
AU690431B2 (en) * 1995-02-17 1998-04-23 Merck & Co., Inc. Method of lessening the risk of non-vertebral bone fractures
US5914099A (en) * 1995-05-12 1999-06-22 Merck & Co., Inc. Prevention of tooth loss by the administration of alendronate or its salts
IL118422A0 (en) * 1995-06-02 1996-09-12 Merck & Co Inc Use of alendronate for the prevention of osteoporosis
JPH11506750A (ja) * 1995-06-06 1999-06-15 メルク エンド カンパニー インコーポレーテッド 慢性関節リウマチに係わる骨欠損に対するビスホスホネート療法
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
US6100301A (en) * 1996-02-28 2000-08-08 Pfizer Inc Combination therapy to treat osteoporosis-polyphosphonates and estrogen agonists
CA2267370A1 (en) * 1996-10-04 1998-04-09 Maneesh J. Nerurkar Liquid alendronate formulations
US6376477B2 (en) 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
US6080779A (en) * 1996-12-13 2000-06-27 Osteoscreen, Inc. Compositions and methods for stimulating bone growth
US6376476B1 (en) * 1996-12-13 2002-04-23 Zymogenetics Corporation Isoprenoid pathway inhibitors for stimulating bone growth
FI104901B (fi) 1997-10-20 2000-04-28 Leiras Oy Uudet metyleenibisfosfonihappojohdannaiset
GB9802617D0 (en) * 1998-02-07 1998-04-01 Knoll Ag Pharmaceutical formulation
US6331533B1 (en) 1998-11-16 2001-12-18 Merck & Co., Inc. Method for inhibiting dental resorptive lesions
US6194469B1 (en) * 1998-12-11 2001-02-27 Board Of Trustees Operating Michigan State Univeristy Method for inhibiting cyclooxygenase and inflammation using cherry bioflavonoids
AU4782600A (en) * 1999-06-02 2000-12-28 Procter & Gamble Company, The Oral preparations of etidronate disodium
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
US6468559B1 (en) 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
CN1224423C (zh) * 2000-07-17 2005-10-26 山之内制药株式会社 改善口服吸收的医药组合物
JP2004519463A (ja) * 2001-01-23 2004-07-02 ガドール エス アー 骨の代謝病の予防および／または治療のための組成物、その組成物の調製方法およびその使用
US7695535B2 (en) 2001-10-10 2010-04-13 River Basin Energy, Inc. Process for in-situ passivation of partially-dried coal
US8197561B2 (en) 2001-10-10 2012-06-12 River Basin Energy, Inc. Process for drying coal
US7537622B2 (en) * 2001-10-10 2009-05-26 Fmi Newcoal, Inc. Process for drying coal
US20030139378A1 (en) * 2001-12-13 2003-07-24 Daifotis Anastasia G. Liquid bisphosphonate formulations for bone disorders
CA2469779C (en) * 2001-12-21 2008-02-12 The Procter & Gamble Company Method for the treatment of bone disorders
CN100551377C (zh) * 2002-05-10 2009-10-21 弗·哈夫曼-拉罗切有限公司 用于治疗和预防骨质疏松症的二膦酸
ITTO20020406A1 (it) * 2002-05-13 2003-11-13 Chiesi Farma Spa Formulazioni di bisfosfonati ad uso iniettabile.
US7041309B2 (en) * 2002-06-13 2006-05-09 Neuropro Technologies, Inc. Spinal fusion using an HMG-CoA reductase inhibitor
GR1004331B (el) * 2002-10-07 2003-09-05 Verisfield (Uk) Ltd Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας αλενδρονικου οξεος
PL212072B1 (pl) * 2002-12-20 2012-08-31 Hoffmann La Roche Tabletka zawierająca jako substancję czynną do 250 mg kwasu ibandronowego oraz sposób jej wytwarzania
US20050101605A1 (en) * 2003-11-07 2005-05-12 Ahmed Salah U. Oral liquid formulations of methotrexate
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
ES2921141T3 (es) * 2004-05-24 2022-08-18 Theramex Hq Uk Ltd Forma farmacéutica oral sólida entérica de un bisfosfonato que contiene un agente quelante
US20080287400A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645460B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US20080286359A1 (en) * 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US20080032959A1 (en) * 2004-06-23 2008-02-07 Alves Stephen E Estrogen Receptor Modulators
EP1796683A1 (en) * 2004-07-15 2007-06-20 Nanobac Life Sciences Methods and compositions for the administration of calcium chelators, bisphosphonates and/or citrate compounds and their pharmaceutical uses
WO2006020009A1 (en) * 2004-07-23 2006-02-23 The Procter & Gamble Company Solid oral dosage form of a bisphosphonate containing a chelating agent
EP1802641B8 (en) * 2004-10-08 2012-03-07 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
WO2007109585A2 (en) * 2006-03-17 2007-09-27 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
WO2008128056A1 (en) * 2004-10-08 2008-10-23 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps
US20060134190A1 (en) * 2004-12-16 2006-06-22 Banner Pharmacaps Inc. Formulations of bisphosphonate drugs with improved bioavailability
US7795427B2 (en) * 2006-02-14 2010-09-14 New York University Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass
PT1894557E (pt) * 2006-09-04 2011-03-02 Gador Sa Composição líquida para a prevenção e/ou tratamento de diferentes doenças metabólicas ósseas, suas utilizações, e processo para a sua preparação
JP2010510230A (ja) * 2006-11-21 2010-04-02 テイコク ファーマ ユーエスエー インコーポレーテッド ビスホスホネート吸入剤及びその使用方法
US8974801B2 (en) * 2006-12-21 2015-03-10 Amphastar Pharmaceuticals Inc. Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
US20090170815A1 (en) * 2007-12-28 2009-07-02 Roxane Laboratories Incorporated. Alendronate oral liquid formulations
CA2711413A1 (en) * 2008-02-05 2009-08-13 Actavis Group Ptc Ehf Alendronate formulations, method of making and method of use thereof
US20100034752A1 (en) * 2008-08-11 2010-02-11 Toru Hibi Inhalant formulations comprising a bisphosphonate and a pyrazolone derivative and methods for using the same
US8956426B2 (en) 2010-04-20 2015-02-17 River Basin Energy, Inc. Method of drying biomass
US9057037B2 (en) 2010-04-20 2015-06-16 River Basin Energy, Inc. Post torrefaction biomass pelletization
US9889225B2 (en) * 2010-08-20 2018-02-13 Kaohsiung Medical University Method for bone formation by administering poly(lactic-co-glycolic acid) cross-linked alendronate
ES2716525T3 (es) * 2010-12-06 2019-06-13 Effrx Pharmaceuticals Sa Formulaciones de bisfosfonatos efervescentes estables con características de solubilización rápida
CN103070824B (zh) * 2013-01-24 2014-07-16 天津红日药业股份有限公司 一种含有伊班膦酸钠的注射液
EP3054980B1 (en) * 2013-10-08 2019-09-04 InnoPharma, Inc. Aprepitant oral liquid formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1187828B (it) * 1985-05-24 1987-12-23 Gentili Ist Spa Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi
GB8618259D0 (en) * 1986-07-25 1986-09-03 Leo Pharm Prod Ltd Pharmaceutical compositions
DE3822650A1 (de) * 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
FI83421C (fi) * 1989-06-21 1991-07-10 Huhtamaeki Oy Foerfarande foer framstaellning av farmakologiskt anvaendbara metylenbisfosfonsyraderivat.
US5227506A (en) * 1989-09-06 1993-07-13 Merck & Co., Inc. Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors
US5356887A (en) * 1990-01-31 1994-10-18 Merck & Co., Inc. Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
CA2035179C (en) * 1990-01-31 2001-08-14 Gerald S. Brenner Pharmaceutical compositions containing insoluble salts of bisphosphonic acids
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
FR2703590B1 (fr) * 1993-04-05 1995-06-30 Sanofi Elf Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .

Also Published As

Publication number Publication date
HU220626B1 (hu) 2002-03-28
IL113651A (en) 1999-08-17
KR100372966B1 (ko) 2003-05-12
ATE222495T1 (de) 2002-09-15
CY2336B1 (en) 2004-02-06
DE69527842D1 (de) 2002-09-26
FI118296B (fi) 2007-09-28
DK0759757T3 (da) 2002-10-07
ES2180646T3 (es) 2003-02-16
MY112285A (en) 2001-05-31
MX9605660A (es) 1998-02-28
NO964864D0 (no) 1996-11-15
NZ289231A (en) 1998-04-27
RU2176507C2 (ru) 2001-12-10
AU691634B2 (en) 1998-05-21
PL320614A1 (en) 1997-10-13
HK1009245A1 (en) 1999-05-28
HU9603162D0 (en) 1997-01-28
FI964593A0 (fi) 1996-11-15
UA29505C2 (uk) 2000-11-15
KR970703151A (ko) 1997-07-03
NO964864L (no) 1996-11-15
CA2190148A1 (en) 1995-11-23
EP0759757A1 (en) 1997-03-05
TW402501B (en) 2000-08-21
CN1148341A (zh) 1997-04-23
SI0759757T1 (en) 2002-12-31
JP4111536B2 (ja) 2008-07-02
CZ285860B6 (cs) 1999-11-17
CA2190148C (en) 2006-02-14
SK281098B6 (sk) 2000-11-07
HRP950293B1 (en) 2003-08-31
EP0759757B1 (en) 2002-08-21
YU49354B (sh) 2005-09-19
CZ336796A3 (en) 1997-06-11
CO4600739A1 (es) 1998-05-08
JPH10504020A (ja) 1998-04-14
FI964593A (fi) 1996-11-15
DZ1884A1 (fr) 2002-02-17
US5462932A (en) 1995-10-31
HUT76317A (en) 1997-08-28
PT759757E (pt) 2002-11-29
ZA953960B (en) 1996-01-19
DE69527842T2 (de) 2003-04-10
CN1079672C (zh) 2002-02-27
SK147796A3 (en) 1997-07-09
WO1995031203A1 (en) 1995-11-23
PL179634B1 (pl) 2000-10-31
NO310179B1 (no) 2001-06-05
AU2901095A (en) 1995-12-05
IL113651A0 (en) 1995-08-31
HRP950293A2 (en) 1997-04-30

Similar Documents

Publication Publication Date Title
HUT76317A (en) Oral liquid alendronate formulations
HK1050313A1 (en) Oral transmucosal drug dosage using solid solution
HUP0000575A2 (hu) Hatóanyagként budesonidot tartalmazó új gyógyszerforma
NZ503946A (en) Oral dosage form in an oval or caplet shape for administration of bisphosphonates and other known medicaments
YU48583B (sh) Postupak za pripremanje formulacije u obliku pilule za oralno davanje
CA2390377A1 (en) Method and apparatus for delivery of controlled doses of therapeutic drugs in endoluminal procedures
PL338982A1 (en) Drug for improving duration of muscle action or for treating muscular disorders or diseases
ATE289199T1 (de) Formulierungen mit dem wasserfreien mononatriumsalz von alendronat und deren verwendung zur behandlung von knochenkrankheiten
WO1999040883A3 (en) Compositions and methods for the treatment of cystic fibrosis
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
CA2180178A1 (en) Use of 2,3-diaryl-1-benzopyran derivatives for the manufacture of a medicament in the treatment and prevention of bone loss and osteoporosis
MY137570A (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis crohn's disease
IL136415A0 (en) Transmucosal formulations of levosimendan
TW200517119A (en) Method of treatment using interferon-tau
EG17992A (en) Preparation of a medicament for arthritis and theumatism
HUP9900521A2 (hu) Eljárás nagyon kis dózisú hatóanyagok szilárd dózisformáinak előállítására
RU98118897A (ru) Способ увеличения массы костной ткани при переломах
PT95867A (pt) Processo para a preparacao de uma composicao de libertacao retardada compreendendo um copolimero de lactide e glicolide, para tratamento de doencas periodonticas